Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

A “very important” part of Merck’s HIV strategy has come off the rails. Just months after talking up the importance of MK-8507, Merck has paused development of the asset in response to mid-phase data that also raised questions about the backbone of all the company’s planned HIV regimens.